Conditions: Acute Myeloid Leukemia
Keywords: Acute myeloid leukemia WT1
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 9
Healthy volunteers: no

Brief summary:
The purpose of this study is to assess the safety, tolerability of OCV-501 in patients with acute myeloid leukemia (AML) who achieved complete remission after induction regimen and who completed a standard consolidation therapy.

Detailed description:

Arms:
arm 1: 0.3 mg arm 2: 1 mg arm 3: 3 mg

Interventions: intervention 1: OCV-501 intervention 2: OCV-501 intervention 3: OCV-501
Intervention descriptions: intervention 1: subcutaneously administered once a week, 4 times at the dose of 0.3 mg intervention 2: subcutaneously administered once a week, 4 times at the dose of 1 mg intervention 3: subcutaneously administered once a week, 4 times at the dose of 3 mg

Protocol document: